Supernus Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SUPN and other ETFs, options, and stocks.

About SUPN

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. 

CEO
Jack A. Khattar
CEOJack A. Khattar
Employees
674
Employees674
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2005
Founded2005
Employees
674
Employees674

SUPN Key Statistics

Market cap
2.96B
Market cap2.96B
Price-Earnings ratio
-149.18
Price-Earnings ratio-149.18
Dividend yield
Dividend yield
Average volume
713.05K
Average volume713.05K
High today
$51.97
High today$51.97
Low today
$50.46
Low today$50.46
Open price
$50.87
Open price$50.87
Volume
684.74K
Volume684.74K
52 Week high
$57.65
52 Week high$57.65
52 Week low
$29.16
52 Week low$29.16

Stock Snapshot

Supernus Pharmaceuticals(SUPN) stock is priced at $51.62, giving the company a market capitalization of 2.96B. It carries a P/E multiple of -149.18.

During the trading session on 2026-02-17, Supernus Pharmaceuticals(SUPN) shares reached a daily high of $51.97 and a low of $50.46. At a current price of $51.62, the stock is +2.3% higher than the low and still -0.7% under the high.

Trading volume for Supernus Pharmaceuticals(SUPN) stock has reached 684.74K, versus its average volume of 713.05K.

Over the past 52 weeks, Supernus Pharmaceuticals(SUPN) stock has traded between a high of $57.65 and a low of $29.16.

Over the past 52 weeks, Supernus Pharmaceuticals(SUPN) stock has traded between a high of $57.65 and a low of $29.16.

SUPN News

Simply Wall St 5d
Assessing Supernus Pharmaceuticals Valuation After Recent Share Price Momentum And Undervalued Narrative

Advertisement Why Supernus Pharmaceuticals (SUPN) Is On Investors’ Radar Today Supernus Pharmaceuticals (SUPN) has drawn fresh attention after recent share pe...

Assessing Supernus Pharmaceuticals Valuation After Recent Share Price Momentum And Undervalued Narrative

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own SUPN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.